 Background: Both, ACE-inhibitors as well as angiotensin-II-type-1 AT1 receptor antagonists seem to reduce the development of type-II diabetes in patients with hypertension andor high vascular risk 1-3. The major drawback of that evidence is that it derives from post-hoc analyses in studies with rather poor metabolic phenotypisation of the populations included. Additionally, all that evidence is based on measurements of fasting plasma glucose. 